Literature DB >> 22847626

Synaptic defects in type I spinal muscular atrophy in human development.

Rebeca Martínez-Hernández1, Sara Bernal, Eva Also-Rallo, Laura Alías, María Jesús Barceló, Marta Hereu, Josep E Esquerda, Eduardo F Tizzano.   

Abstract

Childhood spinal muscular atrophy is an autosomal recessive neuromuscular disorder caused by alterations in the Survival Motor Neuron 1 gene that triggers degeneration of motor neurons within the spinal cord. Spinal muscular atrophy is the second most common severe hereditary disease of infancy and early childhood. In the most severe cases (type I), the disease appears in the first months of life, suggesting defects in fetal development. However, it is not yet known how motor neurons, neuromuscular junctions, and muscle interact in the neuropathology of the disease. We report the structure of presynaptic and postsynaptic apparatus of the neuromuscular junctions in control and spinal muscular atrophy prenatal and postnatal human samples. Qualitative and quantitative data from confocal and electron microscopy studies revealed changes in acetylcholine receptor clustering, abnormal preterminal accumulation of vesicles, and aberrant ultrastructure of nerve terminals in the motor endplates of prenatal type I spinal muscular atrophy samples. Fetuses predicted to develop milder type II disease had a similar appearance to controls. Postnatal muscle of type I spinal muscular atrophy patients showed persistence of the fetal subunit of acetylcholine receptors, suggesting a delay in maturation of neuromuscular junctions. We observed that pathology in the severe form of the disease starts in fetal development and that a defect in maintaining the initial innervation is an early finding of neuromuscular dysfunction. These results will improve our understanding of the spinal muscular atrophy pathogenesis and help to define targets for possible presymptomatic therapy for this disease.
Copyright © 2012 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22847626     DOI: 10.1002/path.4080

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  37 in total

1.  Dissection of the transversus abdominis muscle for whole-mount neuromuscular junction analysis.

Authors:  Lyndsay Murray; Thomas H Gillingwater; Rashmi Kothary
Journal:  J Vis Exp       Date:  2014-01-11       Impact factor: 1.355

2.  Decreased function of survival motor neuron protein impairs endocytic pathways.

Authors:  Maria Dimitriadi; Aaron Derdowski; Geetika Kalloo; Melissa S Maginnis; Patrick O'Hern; Bryn Bliska; Altar Sorkaç; Ken C Q Nguyen; Steven J Cook; George Poulogiannis; Walter J Atwood; David H Hall; Anne C Hart
Journal:  Proc Natl Acad Sci U S A       Date:  2016-07-11       Impact factor: 11.205

Review 3.  Advances in therapy for spinal muscular atrophy: promises and challenges.

Authors:  Ewout J N Groen; Kevin Talbot; Thomas H Gillingwater
Journal:  Nat Rev Neurol       Date:  2018-02-09       Impact factor: 42.937

4.  AAV9-DOK7 gene therapy reduces disease severity in Smn2B/- SMA model mice.

Authors:  Kevin A Kaifer; Eric Villalón; Caley E Smith; Madeline E Simon; Jose Marquez; Abigail E Hopkins; Toni I Morcos; Christian L Lorson
Journal:  Biochem Biophys Res Commun       Date:  2020-07-30       Impact factor: 3.575

5.  Motor neuronal repletion of the NMJ organizer, Agrin, modulates the severity of the spinal muscular atrophy disease phenotype in model mice.

Authors:  Jeong-Ki Kim; Charlotte Caine; Tomoyuki Awano; Ruth Herbst; Umrao R Monani
Journal:  Hum Mol Genet       Date:  2017-07-01       Impact factor: 6.150

6.  Requirement of enhanced Survival Motoneuron protein imposed during neuromuscular junction maturation.

Authors:  Shingo Kariya; Teresa Obis; Caterina Garone; Turgay Akay; Fusako Sera; Shinichi Iwata; Shunichi Homma; Umrao R Monani
Journal:  J Clin Invest       Date:  2014-01-27       Impact factor: 14.808

Review 7.  Spinal muscular atrophy: journeying from bench to bedside.

Authors:  Tomoyuki Awano; Jeong-Ki Kim; Umrao R Monani
Journal:  Neurotherapeutics       Date:  2014-10       Impact factor: 7.620

8.  Dysregulation of synaptogenesis genes antecedes motor neuron pathology in spinal muscular atrophy.

Authors:  Zhenxi Zhang; Anna Maria Pinto; Lili Wan; Wei Wang; Michael G Berg; Isabela Oliva; Larry N Singh; Christopher Dengler; Zhi Wei; Gideon Dreyfuss
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-04       Impact factor: 11.205

Review 9.  Spinal muscular atrophy: a motor neuron disorder or a multi-organ disease?

Authors:  Monir Shababi; Christian L Lorson; Sabine S Rudnik-Schöneborn
Journal:  J Anat       Date:  2013-07-22       Impact factor: 2.610

10.  The DcpS inhibitor RG3039 improves motor function in SMA mice.

Authors:  James P Van Meerbeke; Rebecca M Gibbs; Heather L Plasterer; Wenyan Miao; Zhihua Feng; Ming-Yi Lin; Agnieszka A Rucki; Claribel D Wee; Bing Xia; Shefali Sharma; Vincent Jacques; Darrick K Li; Livio Pellizzoni; James R Rusche; Chien-Ping Ko; Charlotte J Sumner
Journal:  Hum Mol Genet       Date:  2013-05-31       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.